Recent Investigation by Monteverde Associates into Terns Pharmaceuticals' Shareholder Deal The M&A Class Action Firm is probing Terns Pharmaceuticals, focusing on its sale to Merck. Are shareholders getting a fair deal from the $53.00 offer?

Recent Investigation by Monteverde Associates into Terns Pharmaceuticals' Shareholder Deal #United_States #New_York_City #Monteverde_Associates #Terns_Pharmaceuticals #Merck_Sharp